Abstract:The proteome is fundamental to human biology and disease but little is known about ancestral diversity of its genetic determinants. In GWAS of plasma levels of 1,451 proteins in 3,974 Chinese adults, we identified pQTLs for 1,082 proteins, including 743 with at least one cis -pQTL. Fine-mapping defined credible sets for 3,336 independent pQTLs, of which 31% did not overlap with corresponding analyses in European adults. We assessed 777 sentinel cis -pQTLs in phenome-wide MR analyses using GWAS Catalog and identified Bonferroni-significant associations for 22 protein-disease pairs. Among 10 protein-disease pairs identified from East Asian-specific GWAS, four had evidence of colocalisation. Evaluation of current drug development confirmed indications for one protein target, identified potential repurposing for seven, and discovered nine potential novel targets, including GP2 for Type-2-diabetes. The findings demonstrate the importance of extending genome-wide plasma proteomic analyses to non-European ancestry populations to identify potential novel drug targets for major diseases. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up and subsequent resurveys have been supported by Wellcome grants to Oxford University (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (82192901, 82192904, 82192900) and from the National Key Research and Development Program of China (2016YFC0900500).The UK Medical Research Council (MC\_UU\_00017/1, MC\_UU\_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186, C500/A16896) and the British Heart Foundation (CH/1996001/9454), provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit at Oxford University for the project. The proteomic assays were supported by BHF (18/23/33512), Novo Nordisk and Olink. DNA extraction and genotyping were supported by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: N/A I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Full summary statistics data are available at [URL accessible on publication]. Other data presented in this study are included in this publication supplementary information.

Proteome-wide Assessment of 10,000 Plasma Proteins with Age-Related Diseases and Multi-Morbidity in a Chinese Population

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Proteomic Aging Clock Predicts Mortality and Risk of Common Age-Related Diseases in Diverse Populations

Comparative studies of genetic and phenotypic associations for 2,168 plasma proteins measured by two affinity-based platforms in 4,000 Chinese adults

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia

Risk prediction of ischemic heart disease using plasma proteomics, conventional risk factors and polygenic scores in Chinese and European adults

Blood protein assessment of leading incident diseases and mortality in the UK Biobank

Plasma Proteomic Profiles Predict Individual Future Health Risk.

Proteomics in aging research: A roadmap to clinical, translational research

A compact protein panel for organ-specific age and chronic disease prediction

Undulating changes in human plasma proteome profiles across the lifespan

An exposome-wide assessment of 6600 SomaScan proteins with non-genetic factors in Chinese adults

Plasma Proteomics-Based Organ-Specific Aging for All-Cause Mortality and Cause-Specific Mortality: a Prospective Cohort Study

Blood protein levels predict leading incident diseases and mortality in UK Biobank

Age-Dependent Changes in the Plasma Proteome of Healthy Adults

Plasma proteomic signature of human longevity

Proteomic signatures improve risk prediction for common and rare diseases

Ancestry Diversity in the Genetic Determinants of the Human Plasma Proteome and Associated New Drug Targets

Serum Proteomic Signatures of Common Health Outcomes among Older Adults

An exposome-wide investigation of 2923 Olink proteins with non-genetic factors in Chinese adults

Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults